

1 **Single-cell RNA sequencing unraveled the expression heterogeneity of**
2 **hematopoietic stem and progenitor cells and lymphoid cell development**
3 **dysregulation in childhood asthma**

4 Danying Zhu^{*1,2}, Guang Li^{*3}, Lang Yuan^{*1}, Zeyu Zeng^{1,2}, Na Dong¹, Chao Wang¹, Ming
5 Chen¹, Lijian Xie⁵, Guohui Ding^{#,4}, Libing Shen^{#,4}, Xiaoyan Dong^{#,1,2}

6

7 ¹ Department of Pulmonology, Shanghai Children's Hospital, School of medicine, Shanghai
8 Jiao Tong University, Shanghai, China

9 ² Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Jiao Tong
10 University School of Medicine, Shanghai, China.

11 ³ Daozhi Precision Medicine Technology (Shanghai) Co., Ltd; Shanghai, China.

12 ⁴ Institute for Digital Health, International Human Phenome Institutes (Shanghai), Shanghai,
13 China.

14 ⁵ Department of Pediatrics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.

15

16 *These authors contributed equally: Danying Zhu, Guang Li, Lang Yuan

17

18 **#Corresponding authors**

19 Xiaoyan Dong, *Ph.D.*

20 Department of Respiratory, Shanghai Children's Hospital, School of medicine, Shanghai Jiao
21 Tong University, Shanghai, China.

22 Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Jiao Tong
23 University School of Medicine, Shanghai, China.

24 No.355, Luding Road, Shanghai 200062, China.

25 Tel: 18930734642

26 E-mail: dongxy@shchildren.com.cn

27

28 Libing Shen, *Ph.D*

29 Institute for Digital Health, International Human Phenome Institutes (Shanghai), Shanghai,
30 China.

31 12/F, No.258 Guoxia Road, Yangpu District, Shanghai, China.

32 Tel: 13482391370

33 E-mail: shenlibing@ihup.org.cn

34

35 Guohui Ding, *Ph.D.*

36 Institute for Digital Health, International Human Phenome Institutes (Shanghai), Shanghai,

37 China.

38 12/F, No.258 Guoxia Road, Yangpu District, Shanghai, China.

39 [Tel:17721236391](tel:17721236391)

40 Email: dingguohui@ihup.org.cn

41

42

43

44 **Abstract**

45 Asthma is a long-term inflammatory disease affecting airways and lungs with usual
46 onset in childhood. Its cause is not fully understood up to now. Here, using single-cell
47 RNA sequencing, we profile peripheral blood mononuclear cells (PBMCs) from three
48 pediatric patients with onset asthma and four age-matched healthy controls to
49 investigate the cellular etiology of childhood asthma. The overall expression features
50 among three asthma patients' PBMCs demonstrate that innate immunity is commonly
51 upregulated while adaptive immunity is commonly downregulated in childhood
52 asthma, but each patient has different molecular phenotypes. The analyses of the
53 expression profiles of hematopoietic stem and progenitor cells (HSPCs) further show
54 that the HSPCs of asthma patients have heterogeneous expression backgrounds with
55 more specific differentially expressed genes (DEGs) in each patient than common
56 DEGs and a common feature of low S100 protein binding gene expression. S100A8,
57 S100A9, S100A12, and RETN are universally upregulated in various cell types of
58 asthma patients. The cell developmental trajectories in three asthma cases exhibit an
59 abnormal immune cell development pattern compared to that in health control. The
60 dysregulated lymphoid lineage development is observed in all 3 patients, but there is
61 no identical abnormal pattern for each patient. The pseudo-time analyses of gene
62 expression show that the expression dynamics of two proto-oncogenes, JUN and SPI1,
63 and six inflammatory response related genes (S100A8, S100A9, S100A12, IL7R,
64 IL32, CCL5) are relevant to abnormal immune cell development in asthma patients.
65 The cell-cell communication analyses reveal the contribution of incoming annexin
66 signal towards dendritic cells and the outgoing resistin signal from dendritic cells to
67 asthma heterogeneity. Interestingly, the plasma blast cells of asthma patient 3 with
68 severe symptoms exhibit dual cell identities of both plasma blast cells and T cells. Our
69 scRNA-Seq analyses for three asthma patients reveal a complex cellular etiology for
70 childhood asthma and provide a new research direction for the comprehensive and
71 systematic understanding of key molecular mechanisms of childhood asthma.

72

73

74 **Introduction**

75 Asthma, a persistent respiratory condition, is marked by inflammation of the
76 airways, heightened bronchial responsiveness, and variable airway obstruction. This
77 complex disease involves a multitude of cellular participants, including eosinophils, T
78 and B lymphocytes, macrophages, neutrophils, and epithelial cells, which interact
79 with environmental factors to induce chronic inflammation, reversible airflow
80 limitations, and airway remodeling in patients¹. The involvement of various cell types
81 and their mediators is a key aspect of asthma's pathogenesis². This diversity in asthma
82 phenotypes and the intricacy of its pathogenesis are further complicated by the fact
83 that respiratory infections and allergen exposures are known to trigger asthma
84 exacerbations¹. While asthma can affect individuals across all age groups, the
85 manifestation, underlying pathophysiology, and response to treatment can vary
86 significantly between children and adults. Recognizing the molecular and cellular
87 distinctions between childhood and adult asthma is crucial for crafting age-tailored
88 diagnostic and therapeutic approaches.

89 childhood asthma, in particular, presents with distinct clinical and immunological
90 characteristics compared to its adult counterpart. Asthma in children often manifests
91 as allergic phenotypes with a higher incidence of eosinophilic inflammation, whereas
92 adults may display a broader range of subtypes, including non-eosinophilic variants.
93 The immature and plastic nature of the immune system in children can lead to unique
94 cellular responses and immune dysregulation. Therefore, there are some differences in
95 the treatment by unique age groups³. Single-cell sequencing offers a powerful tool to
96 explore age-specific alterations in immune cell populations, their activation states, and
97 functional attributes, providing a deeper understanding of the mechanisms driving
98 childhood asthma.

99 Previous research has predominantly focused on the single-cell sequencing of
100 adult asthma^{4,5}, whereas this study applies single-cell technology to childhood asthma,
101 aiming to uncover the role of immune abnormalities in the pathogenesis of asthma in
102 children. Through single-cell sequencing, specific cell subpopulations can be
103 identified, and their roles in the inflammatory responses of children with asthma can
104 be understood, as well as their responses to current treatment methods. These findings
105 may help explain why childhood asthma exhibits differences in clinical presentation
106 and treatment response compared to adult asthma, and they provide new perspectives
107 for future research and clinical practice.

108 **Method**

109 **Patients**

110 During the initial hospital stay, before any treatment, we collected three fresh
111 peripheral blood samples from patients experiencing acute asthma. The diagnosis of
112 asthma was confirmed using the criteria outlined in the 2023 Global Initiative for
113 Asthma (GINA) report, which can be accessed at [https://ginasthma.org/2023-gina-](https://ginasthma.org/2023-gina-main-report/)
114 [main-report/](https://ginasthma.org/2023-gina-main-report/). Atopic status was determined by a total IgE level of 200 IU/ml or higher.
115 For single-cell RNA sequencing (scRNA-seq), we enrolled four healthy individuals
116 who were participating in routine physical examinations and had no recent history of
117 fever, infection, or immunization. Data from three of these individuals have
118 previously been published⁶. All participants were recruited from Shanghai Children's
119 Hospital between December 2019 and February 2023. Exclusion criteria for the study
120 included: Participants who were undergoing immunotherapy, such as anti-IgE
121 treatment, or had received such therapy within the last three months. Individuals with
122 significant abnormalities identified in their complete blood count. Subjects who were
123 currently enrolled in an asthma-related pharmaceutical or interventional study, or had
124 been part of such a study within the last four weeks. Patients with concurrent medical
125 conditions necessitate systemic corticosteroids or other immunomodulatory
126 treatments. The study was approved by the Ethics Committee of Shanghai Children's
127 Hospital (Protocol Numbers: 2019R081, 2022R029-F-01). Informed consent was
128 obtained from all participants and their guardians.

129

130 **Single-cell preparation and sequencing**

131 A total of 2 milliliters of venous blood was collected from each participant using
132 tubes containing EDTA as an anticoagulant. These samples were processed within
133 four hours to preserve cell integrity. Peripheral blood mononuclear cells (PBMCs)
134 were separated from the collected blood using Ficoll-Paque medium and density
135 gradient centrifugation. The viability of the isolated PBMCs was assessed using
136 trypan blue staining, and only samples with more than 90% viable cells were selected
137 for further analysis. A calculated volume of the cell suspension, estimated to contain
138 around 12,000 cells per sample, was prepared to ensure an adequate cell count for
139 subsequent capture and sequencing processes. The Chromium Next GEM Single Cell

140 V(D)J Reagent Kits v1.1 from 10x Genomics were utilized for capturing single cells
141 and constructing the corresponding libraries. The cell suspension, along with
142 barcoded gel beads and partitioning oil, were loaded onto the 10 × Genomics
143 Chromium Chip to create single-cell Gel Beads-in-Emulsion (GEMs). Inside each
144 GEM, cells were lysed, and their transcripts were barcoded through reverse
145 transcription. After reverse transcription, the cDNA, now carrying cell barcodes,
146 underwent PCR amplification to ensure a sufficient quantity for sequencing. The
147 construction of single-cell RNA sequencing (scRNA-seq) libraries was accomplished
148 using the 5' Library Kits. The prepared libraries were sequenced on an Illumina
149 NovaSeq platform, producing paired-end reads with a length of 2 × 150 base pairs.
150 This sequencing step generates the raw data necessary for subsequent data analysis.

151

152 **scRNA-seq data analysis**

153 The demultiplexed reads were then aligned to the GRCh38 reference genome
154 using the Cell Ranger software suite. This gene-barcode matrix was subsequently
155 analyzed using Seurat version 3.0.2 for various analytical steps, including quality
156 control, data normalization, dimensionality reduction, batch effect correction,
157 clustering, and data visualization. The specific procedures carried out with Seurat
158 included: Applying quality control criteria for the majority of samples, which
159 involved ensuring a total UMI count ranging from 200 to 6000 and limiting the
160 percentages of mitochondrial, hemoglobin, and ribosome genes to below 10%, 0.1%,
161 and 3%, respectively. Integrating samples collected during the initial phase of the
162 study (C1-C4) to eliminate batch effects using anchor. Scaling the integrated matrix
163 and employing the principal components derived from principal component analysis
164 (PCA) for uniform manifold approximation and projection (UMAP). Utilizing UMAP
165 to visualize cells in a two-dimensional space, highlighted their gene expression
166 pattern similarities. Conducting shared nearest neighbor graph-based clustering on the
167 PCA-reduced data to identify the primary cell types within the PBMCs. Examining
168 the expression of canonical marker genes to refine cell cluster annotations.
169 Determining cell identities through multimodal reference mapping with the
170 SeuratDisk package.

171

172 **Differential expression, functional enrichment analysis, and pseudo-time analysis**

173 The marker genes for each cluster were calculated with the FindAllMarkers function
174 within the Seurat package. The clusterProfiler package (version 3.16.0) was used for
175 function over-representation analysis of the differentially expressed genes (DEGs)
176 with a false discovery rate (FDR) threshold of <0.05. Gene Ontology (GO), KEGG
177 pathways, and hallmark gene sets from the MSigDB database (version 7.1) were used
178 as gene function databases to assess the enrichment of specific biological functions or
179 pathways among the DEGs. Pseudo-time analysis of cell differentiation trajectories
180 for each sample dataset was performed with R package Monocle 2⁷. The expression
181 feature and inferred cell type for each sample dataset from the Seurat result were used
182 to annotate the cell dataset for the Monocle analysis pipeline. We used the Monocle
183 built-in approach named “dpFeature” to detect the variable genes that define a cell’s
184 differentiation. Its advantages are needing no prior biological knowledge and
185 discovering important ordering genes from the data itself. Dimension reduction was
186 performed with 2 max components and the “DDRTree” method. Cell-cell
187 communication analysis was performed with the R package CellChat 1.6.1⁸.

188

189 **Human serum resistin Enzyme-Linked Immunosorbent Assay (ELISA) analysis**

190 EDTA-anticoagulated whole blood was transferred to the laboratory and
191 processed immediately after collection. Centrifuge samples for 15 minutes at 1000 x g
192 at 4 °C within 30 minutes of collection and stored at -80 °C. We followed a human
193 resistin ELISA kit (Signalway Antibody, Maryland, USA, Catalog No: EK2351)
194 protocol to analyze peripheral blood serums.

195

196 **Results**

197 **Characteristics of the study subjects for asthma patients and health controls**

198 In our single-cell RNA analysis study, we included a cohort of 7 childhood
199 subjects, comprising 3 children experiencing asthma exacerbations and 4 healthy
200 individuals without asthma. The mean age of the participants ranges from 1 to 9
201 years old. An additional group of 14 asthma patients and health controls ranging from
202 1 to 13 years old, were included in the study. Allergic testing in asthmatic children
203 revealed sensitization to house dust mites. Allergic testing in asthmatic children
204 revealed sensitization to house dust mites.

205

206 **Single-cell RNA profiling of PBMCs in health and asthma patients**

207 We collected the peripheral blood samples derived from 3 patients with onset
208 asthma (A1-A3). The patients were diagnosed according to the GINA 2023
209 (<https://ginasthma.org/2023-gina-main-report/>). For each patient, the blood sample
210 was taken on the first days before therapy. We also collected fresh peripheral blood
211 samples from four age-matched healthy donors as controls (C1–C4).

212 We used the 10× Genomics platform for scRNA-seq of PBMCs isolated from the
213 samples. PBMCs were loaded onto the platform and about 5000 - 14000 cells per
214 sample could be recovered from the sequencing data. The total number of detected
215 cells passing quality control was 34,354 for 3 asthma patients and 22,398 cells from
216 healthy controls. Based on the scRNA-seq profiles, we clustered the cells across
217 samples with Seurat 4.0 and visualized them in two-dimensional space (Fig. 1a). The
218 PBMCs in our study could be clustered into 12 major cell types including B cells,
219 CD4 T cells, CD8 T cells, CD14 monocytes (CD14 mono), CD16 monocytes (CD16
220 mono), dendritic cells (DC), mucosa-associated invariant T cells (MAIT), gamma-
221 delta cells (gdT), hematopoietic stem and progenitor cells (HSPC), natural killer cells
222 (NK), plasma blast cells (Plasmablast), and platelets. Each cell type was verified with
223 PBMC multimodal reference object and canonical gene markers (Supplementary
224 Figure 1a and 1b). The percentage of major cell types for each sample is shown in
225 Figure 1b. The more detailed classification of cell types excluding CD4 T and CD8 T
226 cells shows that CD14 monocytes are significantly increased and CD16 monocytes
227 are significantly decreased in asthma patients (Figure 1c, P -value < 0.05). The
228 detailed classification of T cell types in each sample is shown in Supplementary
229 Figure 1c.

230

231 **Expression features of all cells and HSPCs in asthma patients**

232 We first compared the gene expression level of all cells in each asthma patient to
233 controls. The overall differentially expressed genes (DEGs) were identified for each
234 asthma patient. There are 174 upregulated genes in A1 (Asthma1), 29 upregulated
235 genes in A2 (Asthma2), and 246 upregulated genes in A3 (Asthma3) (Figure 2a).
236 There are 21 common upregulated genes among three asthma patients. GO analysis
237 shows that these commonly upregulated genes are involved in the extracellular region,

238 secretion, and antimicrobial function (Figure 2b). GO result also shows that innate
239 immunity plays a major role in childhood asthma which manifests as a defense
240 response to bacterium and inflammatory response. There are 57 specific upregulated
241 genes in A1, 3 specific upregulated genes in A2, and 128 specifically upregulated
242 genes in A3. GO analyses of the specifically upregulated genes in A1 and A3 show
243 that these two patients have different molecular phenotypes (Supplemental Tables 1
244 and 2). A1 exhibits the specific expression of signal sequences (usually 20-30 amino
245 acids long) and positive regulation of T cell migration while A3 has an excessive
246 expression of immunoglobulin. 3 specific upregulated genes in A2 are IGHV3-73,
247 CDK6 and NELL2 which are not sufficient for GO analysis. We also find 33
248 downregulated genes in A1 (Asthma1), 80 downregulated genes in A2 (Asthma2), and
249 66 downregulated genes in A3 (Asthma3) (Figure 2c). There are 9 common
250 upregulated genes among three asthma patients. GO analysis shows that these
251 common downregulated genes are involved in adaptive immunity and T cell receptor
252 (Figure 2d). There are 13 specific downregulated genes in A1, 37 specific
253 downregulated genes in A2, and 20 specific downregulated genes in A3. A1 exhibits
254 the specific repression of the external side of the plasma membrane and B cell
255 receptor signaling pathway expression (Supplemental Table 3). A2 exhibits the
256 specific repression of the immunoglobulin complex (Supplemental Table 4). A3
257 exhibits the specific repression of the T cell receptor complex (Supplemental Table 5).

258

259 We further examined the expression features of HSPCs in asthma patients, because
260 the other types of cells are all derived from them. There are 176 upregulated HSPC
261 genes in A1 (Asthma1), 211 upregulated HSPC genes in A2 (Asthma2), and 199
262 HSPC upregulated genes in A3 (Asthma3) (Figure 3a). There are 81 common
263 upregulated HSPC genes among three asthma patients. GO analysis shows that these
264 commonly upregulated HSPC genes are mainly involved in the cellular components
265 of extracellular exosome and ER to Golgi transport vesicle membrane (Figure 3b).
266 There are 29 specifically upregulated HSPC genes in A1, 72 specifically upregulated
267 HSPC genes in A2, and 55 specifically upregulated HSPC genes in A3. No significant
268 GO result is found for 29 specifically upregulated HSPC genes in A1. HSPCs in A2
269 exhibit a specific expression of extracellular exosome related genes and HSPCs in A3
270 exhibit a specific expression of endoplasmic reticulum related genes (Supplemental
271 Tables 6 and 7). There are 179 downregulated HSPC genes found in A1 (Asthma1),

272 203 downregulated HSPC genes found in A2 (Asthma2), and 119 HSPC
273 downregulated genes found in A3 (Asthma3) (Figure 3c). GO analysis shows that
274 these common downregulated HSPC genes are mainly involved in S100 protein
275 binding (Figure 3d). There are 85 specifically downregulated HSPC genes in A1, 113
276 specifically downregulated HSPC genes in A2, and 53 specifically downregulated
277 HSPC genes in A3. HSPCs in A1 exhibit a specific repression of adaptive immunity
278 and T cell receptor complex expression (Supplemental Table 8). HSPCs in A2 exhibit
279 a specific repression of immune response related genes' expression (Supplemental
280 Table 9). HSPCs in A3 exhibit a specific repression of extracellular exosome and
281 immunity relate genes' expression (Supplemental Table 10). Interestingly, we find that
282 T cell receptor genes are repressed in all three asthma patients, although they are not
283 statically significant in the HSPCs of A2 and A3 (Supplemental Tables 9 and 10).

284

285 In expression feature analyses, we find that S100A8, S100A9, S100A12, and RETN
286 are universally upregulated in various cell types of asthma patients, especially
287 S100A8 and S100A9 (Figure 4). S100A8, S100A9, and S100A12 are known for
288 participating in inflammatory response while RETN has antibacterial activity⁹⁻¹¹.

289

290 **Single-cell trajectory reconstructions of PBMCs in health controls and 3 asthma** 291 **patients**

292 The expression features of asthma patients' HSPCs demonstrate that the expression of
293 immunity and T cell receptor genes are abnormally repressed in them. Since HSPCs
294 give rise to the other cells, it is worth investigating the cell developmental states in
295 asthma patients. Single-cell trajectory analysis could help us reconstruct the cell
296 developmental paths of PBMCs based on featured variable genes. The analyses show
297 that the PBMCs in healthy controls can be divided into 5 developmental states while
298 the PBMCs in asthma patients have 7, 3, and 5 developmental states, differently
299 (Figure 5a, 5c, 5e, and 5g). All cell types are plotted on each trajectory in each sample
300 (Figure 5b, 5d, 5f, and 5h).

301

302 Based on the major cell types and numbers, state 1 in healthy controls can be
303 classified as B lineage, state 2 can be classified as monocyte lineage, state 3 is a
304 mixed lineage (B and T), state 4 can be classified as T lineage, and state 5 can be

305 classified as T-NK lineage (Figure 3b and Supplement Figure 2a). Myeloid lineage
306 (monocytes) and two lymphoid lineages (B cells and T cells) are clearly differentiated
307 in the PBMCs of healthy controls. However, the clear cell development patterns
308 disappear in 3 asthma patients. Each patient exhibits unique cell developmental
309 patterns different from healthy controls. A1 has 7 states and 4 of them are T lineages
310 according to the major cell numbers (state 1, 2, 3, and 6, Figure 5d and Supplement
311 Figure 2b). A2 has only 3 states and a part of B cells are mixed with T cells (state 1,
312 Figure 5f and Supplement Figure 2c). A3 has 5 states, but B cells are mixed with T
313 cells in state 3 (state 1, Figure 5h and Supplement Figure 2d). Although different
314 childhood asthma patient has a different cell developmental state, abnormal lymphoid
315 lineage development is observed in all 3 patients (multiple T lineage states or no clear
316 B lineage state). This result is consistent with the expression feature analyses showing
317 that adaptive immunity is repressed in asthma patients. T cells and B cells are a major
318 constitution of adaptive immune system and their poor development naturally leads to
319 insufficient the adaptive immunity.

320

321 **Pseudo-time expression dynamic analyses of proto-oncogenes and inflammatory** 322 **response related genes**

323 The abnormal cell developmental trajectories in asthma patients should be
324 accompanied by abnormal gene expression patterns. JUN gene is a transcription factor
325 regulated by various extracellular stimuli including peptide growth factors, pro-
326 inflammatory cytokines, and even UV irradiation¹². SPI1 gene is also a transcription
327 factor regulating gene expression during myeloid and B-lymphoid cell development¹³.
328 Both of them are proto-oncogenes essential for cellular differentiation^{14,15}. We further
329 include six inflammatory response related genes in pseudo-time expression dynamic
330 analyses. Their express dynamics were plotted along cell developmental trajectories
331 in both health control and three asthma patients.

332

333 In health controls, we observed the onset expression of JUN in the early pseudo-time
334 state and a peak expression of six inflammatory response related genes in the early-
335 middle pseudo-time state. SPI1 is expressed in the late pseudo-time state (Figure 6a).
336 In A1 and A2, the expression dynamics of JUN, SPI1, and six inflammatory response
337 related genes are almost the same (Figure 6b and 6c). JUN's onset expression is

338 repressed while SPI1 exhibits an onset expression in the early pseudo-time state.
339 S100A8, S100A9, and S100A12 show an early onset expression rather than a peak
340 expression in the early-middle pseudo-time state. IL7R, IL32, and CCL5 start to
341 express in the early-middle pseudo-time state as health control, but they show a
342 persistent expression level instead of an obvious expression peak. Notably, IL7R,
343 IL32, and CCL5 all participate in the biological process of negative regulation of the
344 T cell apoptotic process (GO:0070233). It implies that the T cells have prolonged cell
345 survival in A1 and A2. A3 shows a different expression dynamic pattern from health
346 control, A1, and A2 (Figure 6d). In A3, JUN is also repressed while the expression
347 patterns of IL7R, IL32, and CCL5 are more similar to health control. S100A8,
348 S100A9, S100A12, and SPI1 show a persistent expression level without decline.
349 Since SPI1 activates gene expression during myeloid and B-lymphoid cell
350 development and S100 protein family plays a role in cell growth and differentiation,
351 their persistent expression pattern indicates an abnormal lymphoid cell development
352 fate in A3.

353

354 **DCs function as a signaling hub in cell communication and play a role in asthma** 355 **heterogeneity**

356 We performed cell communication analyses for both health control and asthma
357 patients to investigate their cell-cell interactions. The number of interactions and
358 interaction strength for health control and three asthma patients are shown in Figure 7 .
359 Generally, asthma patients have a weaker interaction strength than health control and
360 A3 has the smallest number of interactions and the weakest interaction strength
361 among four samples. Among the major immune cell types, we find that dendritic cells
362 have the largest number of both incoming and outgoing interaction
363 numbers(Supplemental Figure 3a, 3b, 3c, and 3d). DCs are known to be the
364 messenger cells communicating between innate and adaptive immune systems¹⁶. They
365 are also known as the antigen presenting cells which interact with T cells and B cells
366 to activate and regulate the adaptive immune response¹⁷. Although DCs don't have the
367 strongest interaction strength among the major immune cell types (Supplemental
368 Figure 4a, 4b, 4c, and 4d), they surely function as a signaling hub in cell
369 communication based on cell communication analyses.

370

371 We further examined the DCs' signaling differences between health control and

372 asthma patients. Using health control as a signaling background, the signaling
373 changes were detected in three asthma patients. The DCs of A1 has a specific
374 incoming signal of annexin (Supplemental Figure 5a). The DCs of A2 has a specific
375 outgoing signal of resistin (Supplemental Figure 5b). The DCs of A3 has a specific
376 incoming signal of annexin and a specific outgoing signal of resistin (Supplemental
377 Figure 5c). Annexin A1, A2 and A5 have a role in the regulation of inflammation
378 activation and may serve as the potential biomarkers for asthma¹⁸⁻²⁰. They all show an
379 elevated expression tendency in asthma cases (Supplemental Figure 6). Resistin also
380 serves a potential biomarker for asthma and is related to inflammation as well^{21, 22}.
381 Our results show that annexin and resistin are actually two opposite directional signals
382 for the DCs of asthma patients. One of them is a sufficient predictor of asthma and
383 both of them indicate a severe symptom of asthma, since A3 is an acute severe asthma
384 patient. Both annexin and resistin show a self-reinforce trend in the CD14 monocytes
385 of asthma patients (Figure 8a and 8b). The upregulated signaling interactions in
386 asthma are mainly centered on the molecular component of external side of plasma
387 membrane and cell adhesion molecules (GO:0009897 and hsa04514, Supplemental
388 Figure 7a, 7b, and 7c). Furthermore, we found that CLEC2B-KLRB1 and LGALS9-
389 CD44 signaling interactions are downregulated in all three asthma patients
390 (Supplemental Figure 8a, 8b, and 8c). CLEC2B-KLRB1 interaction mediates the
391 activation of NK cells and monocytes²³. LGALS9-CD44 interaction enhances the
392 stability and function of adaptive regulatory T cells²⁴. The down-regulated CLEC2B-
393 KLRB1 and LGALS9-CD44 interactions proposes a weakened functions of NK cells,
394 monocytes and T cells in asthma patients.

395

396 **Plasma blast cells in A3 express T cell receptor genes**

397 Patient A3, a severe asthma sufferer who has been admitted to the pediatric intensive
398 care unit, exhibits a unique group of cells not present in healthy controls A1 and A2
399 (Figure 1a). This group predominantly consists of plasma blast cells along with a
400 mixed cluster comprising plasma blast cells (35.2%), erythrocytes (26.5%), CD14
401 monocytes (14.4%), CD4 T cells (11.2%), CD8 T cells (7.7%), and other cells (5%).

402

403 Upon comparing the gene expression profile of A3's plasma blast cells with those of
404 the healthy controls, A1 and A2, we discovered an unexpected finding: the plasma
405 blast cells in A3 express a range of T cell receptor genes, including TRBV20-1, in

406 addition to immunoglobulins (Figure 9a). Further investigation into the expression
407 levels of classical markers for plasma blast cells (CD38, CD19, CD27), CD4 T cells
408 (CD8A, CD27), CD8 T cells (CD40LG, CD27), and NK cells (GNLY, NKG7)
409 revealed through a violin plot that all these markers are indeed expressed in A3's
410 plasma blast cells (Figure 9b). This suggests that the plasma blast cells in A3 likely
411 possess dual cellular identities, exhibiting characteristics of both plasma blast cells
412 and T cells, which accounts for the expression of T cell receptor genes.

413

414 **The expression level of RETN in lymphoid lineage cells**

415 The feature plot shows that the RETN expression is not evenly distributed among
416 different cell clusters. CD14 mono, CD16 mono, and dendritic cells have an
417 especially high expression level of RETN. The violin plot further shows that RETN
418 expression level in these four clusters is always higher in 3 asthma cases than in
419 healthy controls. RETN encodes resistin, then we tested the level of resistin in
420 plasma between children with asthma and healthy controls, we found that resistin in
421 the serum increased significantly in the asthma group than in controls (Figure 10).

422

423 **Discussions**

424 In individuals with allergic airway disease, such as allergic asthma, the airways are
425 already sensitized to specific allergens. This means that the immune system has
426 developed an exaggerated response to these allergens, leading to chronic
427 inflammation and airway hyperresponsiveness. During an asthma exacerbation, this
428 preexisting allergic airway disease is further aggravated by additional inflammatory
429 stimuli or triggers. Nevertheless, the etiology of childhood asthma is so far poorly
430 understood²⁵.

431

432 The analyses of PBMCs from three childhood asthma patients show that childhood
433 asthma is a complex disease with distinct individualities at the cellular level. The
434 overall expression features among three asthma patients' PBMCs demonstrate that
435 innate immunity is commonly upregulated while adaptive immunity is commonly
436 downregulated in childhood asthma, but each patient has different molecular
437 phenotypes. The common upregulated genes in the HSPCs of asthma patient are
438 related to the cellular components of extracellular exosome and ER to Golgi transport
439 vesicle membrane and the common downregulated genes in the HSPCs of asthma

440 patients are related to S100 protein binding. The specific downregulated genes in the
441 HSPCs of each asthma patients converge on immunity and T cell receptor related
442 biological entities. Because HSPCs give the rise to the other cells, they are a cellular
443 source of immunity. The expression abnormality in HSPCs would surely influence
444 their descendant cells. The downregulation of S100 protein binding in the HSPCs
445 indicates that S100 proteins are in an active form in the HSPCs of asthma patients.
446 The downregulation of immunity related genes in HSPCs is a sign of hypo-immune
447 tendency started from the cellular source in asthma cases. The active S100 protein and
448 hypo-immune tendency in the HSPCs of asthma patients seem to lead to over innate
449 immunity and low adaptive immunity for all cells of asthma patients. Although
450 childhood asthma has common pathophysiological features at the cellular level, there
451 are more specific differentially expressed genes (DEGs) in each patient than common
452 DEGs, which proposes that the genetic causes of asthma vary across different children
453 or different allergens can trigger different immune genes in a pediatric patient's
454 immune system. These two explanations are mutually inclusive. Future studies
455 includes bone marrow samples might give us much clearer views for this question,
456 since HSPCs are generated from bone marrow.

457

458 The single-cell trajectory analyses further demonstrate the cell developmental
459 heterogeneities among asthma patients. Different asthma patient has different
460 developmental states. The abnormal lymphoid lineage development is observed in all
461 3 patients. A1 has multiple T cell states while A2 and A3 have a poorly developed
462 lymphoid state of mixed B and T cells. The expression of T cell receptor genes is
463 repressed in the HSPCs of all three asthma patients, although this repression is not
464 statically significant in A2 and A3. It could partly explain the abnormal cell
465 developmental states in asthma patients and the developmental heterogeneities among
466 them. The delayed expression of T cell receptor genes could lead to the HSPC's
467 descendant cells having difficulty receiving the lymphoid development signals. In A1,
468 such deficiency is responded to the development of multiple T cell states by A1's
469 immune system, which seems to compensate for the lack of a proper T cell
470 developmental state. In A2 and A3, the delayed expression of T cell receptor genes is
471 less severe than that in A1, which leads to the underdevelopment of lymphoid lineage.
472 The abnormal single-cell developmental trajectories in asthma patients are also
473 accompanied by the key genes' aberrant expression dynamics. JUN and SPI1 are two

474 proto-oncogenes, both of which have multiple functions in cell fate decisions^{15, 26}. The
475 expression of JUN is repressed in the early stage of cell trajectories for all three
476 asthma patients. It indicates that the cell developmental fate of asthma patients has
477 trouble at the very beginning, which is consistent with the expression abnormality in
478 the HSPCs of asthma patients. In A1 and A2, the repression of JUN seems to be
479 replaced by the expression of SPI1. In A3, the beginning of the expression of SPI1 is
480 consistent with that in health control, but the expression of SPI1 shows no decline like
481 in health control. It implies that the developmental fates of distal cells in A3 could be
482 influenced by SPI1.

483

484 The cell-cell communication analyses further revealed the possible mechanisms
485 underlying the etiology of asthma. Although the number of cell-cell interactions is
486 similar in health control and asthma cases, the strength of cell-cell interactions is
487 much weaker in asthma patients, especially in A3. The overall weak signaling strength
488 is a clear sign of cell-cell communication disorder in asthma. It is in accordance with
489 the abnormal cell developmental trajectories of asthma. DCs induce primary immune
490 responses by processing and presenting antigen material on the cell surface of T
491 cells²⁷. They function as the signaling hub communicating between innate and
492 adaptive immune systems. Two aberrant signals, annexin, and resistin, are found for
493 the DCs of asthma, both of which play a part in inflammatory response. Inflammation
494 is a generic immune response and is considered as a mechanism of innate immunity. It
495 explains why innate immunity is hyperactive in asthma patients. In our cases, each
496 asthma patient has his or her aberrant signaling pattern, annexin for A1, resistin for A2,
497 and both annexin and resistin for A3. It further explains the heterogeneities among
498 asthma patients. Resistin as an outgoing signal from DCs has been reported as a
499 predictor of asthma²¹. Our ELISA results show that its expression can be detected in
500 12 enlisted childhood asthma patients.

501

502 A3 is a special case in our study for the patient with severe symptoms compared to A1
503 and A2 whose symptoms are mild. Severe asthma means strong inflammation in
504 patient's airway which further causes breathlessness and continuous cough. The
505 profiling of A3's PBMCs first presents the patient's severity in our study. A3 has two
506 extra cell clusters compared with health control, A1 and A2. These two extra cell
507 clusters are annotated as mixed cells and plasma blast cells. The UMAP plot shows

508 that the mixed cells and plasma blast cells in A3 are stemmed from CD4 T cells. The
509 expression features of A3's plasma blast cells demonstrate that they express T cell
510 receptor genes as well. It is noticed that SPI1 has a persistent expression dynamic in
511 A3. That A3's plasma blast cells show a duality of T cell identity could be linked to
512 the SPI1's aberrant expression pattern. SPI1 might influence the developmental fate of
513 plasma blast cells in A3 and further exacerbate the patient's symptoms.

514

515 **Conclusions**

516 Our research substantiates that childhood asthma is a multifaceted disease
517 characterized by an upregulation of the innate immune system and a downregulation
518 of the adaptive immune response. Single-cell RNA profiling of PBMCs from asthma
519 patients has uncovered a variety of expression patterns among HSPCs, along with
520 aberrant cell developmental trajectories and diminished cell-cell interaction signaling.
521 While significant heterogeneity exists among different cases of asthma, the
522 pathological features converge on certain commonalities, particularly the abnormal
523 development of the lymphoid lineage and an overabundance of expression in genes
524 related to S100 protein binding and immune response. Notably, S100A8, S100A9,
525 S100A12, and RETN, along with ANXA1, ANXA2, and ANXA5, have emerged as
526 pivotal molecular markers in asthma, directly implicated in the inflammatory response.

527

528 **Contributions**

529 Xiaoyan Dong and Guohui Ding designed the study. Danying Zhu wrote the
530 manuscript. Libing Shen analysis the data. Zeyu Zeng did literature search. Lang Yuan
531 and Na Dong contributed clinical samples. Chao Wang and Ming Chen collected the
532 clinical data. Lijian Xie and Xiaoyan Dong funded the single cell sequencing.

533

534 **Declaration of interests**

535 The authors declare no competing interests.

536

537 **Acknowledgements**

538 This study was funded by Jinshan Distinct key medical specialty project
539 (JSZK2023A04) and Institute of Pediatric Infection, Immunity, and Critical Care

540 Medicine Cultivate Research Project.

541

542 **Data Sharing Statement**

543 All data generated or analyzed during this study are included in this article. Further

544 enquiries can be directed to the corresponding author.

545

546 **References**

- 547 1. Tang W, Li M, Teng F, Cui J, Dong J, Wang W. Single-cell RNA-sequencing in asthma research.
548 *Front Immunol.* 2022;13:988573. doi:10.3389/fimmu.2022.988573
- 549 2. Victor JR, Lezmi G, Leite-de-Moraes M. New Insights into Asthma Inflammation: Focus on iNKT,
550 MAIT, and gammadeltaT Cells. *Clin Rev Allergy Immunol.* Dec 2020;59(3):371-381.
551 doi:10.1007/s12016-020-08784-8
- 552 3. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021:
553 Executive Summary and Rationale for Key Changes. *Am J Respir Crit Care Med.* Jan 1
554 2022;205(1):17-35. doi:10.1164/rccm.202109-2205PP
- 555 4. Alladina J, Smith NP, Kooistra T, et al. A human model of asthma exacerbation reveals
556 transcriptional programs and cell circuits specific to allergic asthma. *Sci Immunol.* May 12
557 2023;8(83):eabq6352. doi:10.1126/sciimmunol.abq6352
- 558 5. Li H, Wang H, Sokulsky L, et al. Single-cell transcriptomic analysis reveals key immune cell
559 phenotypes in the lungs of patients with asthma exacerbation. *J Allergy Clin Immunol.* Mar
560 2021;147(3):941-954. doi:10.1016/j.jaci.2020.09.032
- 561 6. Wang Z, Xie L, Ding G, et al. Single-cell RNA sequencing of peripheral blood mononuclear cells
562 from acute Kawasaki disease patients. *Nat Commun.* Sep 14 2021;12(1):5444. doi:10.1038/s41467-
563 021-25771-5
- 564 7. Qiu X, Mao Q, Tang Y, et al. Reversed graph embedding resolves complex single-cell trajectories.
565 *Nat Methods.* Oct 2017;14(10):979-982. doi:10.1038/nmeth.4402
- 566 8. Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using
567 CellChat. *Nat Commun.* Feb 17 2021;12(1):1088. doi:10.1038/s41467-021-21246-9
- 568 9. Shah RD, Xue C, Zhang H, et al. Expression of Calgranulin Genes S100A8, S100A9 and
569 S100A12 Is Modulated by n-3 PUFA during Inflammation in Adipose Tissue and Mononuclear Cells.
570 *PLoS One.* 2017;12(1):e0169614. doi:10.1371/journal.pone.0169614
- 571 10. Harris TA, Gattu S, Propheter DC, et al. Resistin-like Molecule alpha Provides Vitamin-A-
572 Dependent Antimicrobial Protection in the Skin. *Cell Host Microbe.* Jun 12 2019;25(6):777-788 e8.
573 doi:10.1016/j.chom.2019.04.004
- 574 11. Propheter DC, Chara AL, Harris TA, Ruhn KA, Hooper LV. Resistin-like molecule beta is a
575 bactericidal protein that promotes spatial segregation of the microbiota and the colonic epithelium.

- 576 *Proc Natl Acad Sci U S A*. Oct 17 2017;114(42):11027-11033. doi:10.1073/pnas.1711395114
- 577 12. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct
578 mechanisms. *Embo j*. Jan 4 1999;18(1):188-97. doi:10.1093/emboj/18.1.188
- 579 13. Burda P, Laslo P, Stopka T. The role of PU.1 and GATA-1 transcription factors during normal and
580 leukemogenic hematopoiesis. *Leukemia*. Jul 2010;24(7):1249-57. doi:10.1038/leu.2010.104
- 581 14. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its
582 product, Jun/AP-1. *Cell*. Dec 2 1988;55(5):875-85. doi:10.1016/0092-8674(88)90143-2
- 583 15. Ray D, Culine S, Tavittain A, Moreau-Gachelin F. The human homologue of the putative proto-
584 oncogene Spi-1: characterization and expression in tumors. *Oncogene*. May 1990;5(5):663-8.
- 585 16. Monga I, Kaur K, Dhanda SK. Revisiting hematopoiesis: applications of the bulk and single-cell
586 transcriptomics dissecting transcriptional heterogeneity in hematopoietic stem cells. *Brief Funct*
587 *Genomics*. May 21 2022;21(3):159-176. doi:10.1093/bfpg/elac002
- 588 17. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature*. Mar 19
589 1998;392(6673):245-52. doi:10.1038/32588
- 590 18. Lee SH, Lee PH, Kim BG, et al. Annexin A1 in plasma from patients with bronchial asthma: its
591 association with lung function. *BMC Pulm Med*. Jan 4 2018;18(1):1. doi:10.1186/s12890-017-0557-5
- 592 19. Dallacasagrande V, Hajjar KA. Annexin A2 in Inflammation and Host Defense. *Cells*. Jun 19
593 2020;9(6)doi:10.3390/cells9061499
- 594 20. Lee SH, Lee PH, Kim BG, Hong J, Jang AS. Annexin A5 Protein as a Potential Biomarker for the
595 Diagnosis of Asthma. *Lung*. Dec 2018;196(6):681-689. doi:10.1007/s00408-018-0159-x
- 596 21. Ballantyne D, Scott H, MacDonald-Wicks L, Gibson PG, Wood LG. Resistin is a predictor of
597 asthma risk and resistin:adiponectin ratio is a negative predictor of lung function in asthma. *Clin Exp*
598 *Allergy*. Aug 2016;46(8):1056-65. doi:10.1111/cea.12742
- 599 22. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Resistin, a new adipokine, is related to
600 inflammation and renal function in kidney allograft recipients. *Transplant Proc*. Dec
601 2006;38(10):3434-6. doi:10.1016/j.transproceed.2006.10.140
- 602 23. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and
603 monocytes mediated by NKp80-AICL interaction. *Nat Immunol*. Dec 2006;7(12):1334-42.
604 doi:10.1038/ni1402
- 605 24. Wu C, Thalhamer T, Franca RF, et al. Galectin-9-CD44 interaction enhances stability and function

606 of adaptive regulatory T cells. *Immunity*. Aug 21 2014;41(2):270-82.

607 doi:10.1016/j.immuni.2014.06.011

608 25. Martinez FD. Genes, environments, development and asthma: a reappraisal. *Eur Respir J*. Jan

609 2007;29(1):179-84. doi:10.1183/09031936.00087906

610 26. Vogt PK. Fortuitous convergences: the beginnings of JUN. *Nat Rev Cancer*. Jun 2002;2(6):465-9.


611 doi:10.1038/nrc818

612 27. Kelly RR. Microcomputers in education: age of romance, or age of reason? *Am Ann Deaf*. Sep

613 1982;127(5):693-7. doi:10.1353/aad.2012.1147

614

615 **Figures and figure legends**




616

617 **Figure 1.** Single-cell profiling of PBMCs in six samples. A. The integration single-
 618 cell profiling analysis of six samples including 4 healthy controls, asthma patient 1,
 619 asthma patient 2, and asthma patient 3. B. The percentage bar chart shows the
 620 content of different cell types in each sample. C. The percentage bar chart shows the
 621 different cell types except T cells in each sample.

622

623



624

625 **Figure 2.** The analysis of upregulated and downregulated genes in asthma patients. A.


626 Venn gram of the upregulated genes in 3 asthma patients. B. GO term enrichment

627 analysis of the specific upregulated genes in 3 asthma patients. C. Venn gram of the


628 downregulated genes in 3 asthma patients. D. GO term enrichment analysis of the

629 specific downregulated genes in 3 asthma patients.


630




631 **Figure 3.** The analysis of upregulated and downregulated genes in asthma patients'
 632 HSPC. A. Venn gram of the upregulated genes in 3 asthma patients' HSPC. B. GO
 633 term enrichment analysis of the specific upregulated genes in 3 asthma patients'
 634 HSPC. C. Venn gram of the downregulated genes in 3 asthma patients' HSPC. D. GO
 635 term enrichment analysis of the specific downregulated genes in 3 asthma patients'
 636 HSPC.
 637




638 **Figure 4.** The violin plot of S100A9, S100A8, S100A12 and RETN gene expression
639 levels across different cell types for four sample groups.
640



641 **Figure 5.** Pseudo-time analysis of all cells in four sample groups. A. The
642 differentiation trajectory of all cells in healthy controls by state. B. The differentiation
643 trajectory of all cells in healthy controls by cell types. C. The differentiation trajectory
644 of all cells in asthma patient 1 (Ast1) by state. D. The differentiation trajectory of all
645 cells in asthma patient 1 (Ast1) by cell types. E. The differentiation trajectory of all
646 cells in asthma patient 2 (Ast2) by state. F. The differentiation trajectory of all cells in
647 asthma patient 2 (Ast2) by cell types. G. The differentiation trajectory of all cells in
648 asthma patient 3 (Ast3) by state. H. The differentiation trajectory of all cells in asthma
649 patient 3 (Ast3) by cell types.




650 **Figure 6.** Pseudo-time analyses of expression dynamics of two cell-fate and
651 inflammation related genes in four sample groups. A. Expression dynamics two cell-
652 fate and six inflammation related genes in health control. B. Expression dynamics two
653 cell-fate and six inflammation related genes in health control in asthma patient 1
654 (Ast1). C. Expression dynamics two cell-fate and six inflammation related genes in
655 health control in asthma patient 2 (Ast2). D. Expression dynamics two cell-fate and
656 six inflammation related genes in health control in asthma patient 3 (Ast3).
657




658 **Figure 7.** The number of cell-cell interactions and interaction strength for four sample
659 groups.


660



661 **Figure 8.** The annexin and resistin signaling pathway network of four sample groups.
662 The annexin signaling pathway network is shown for health control, asthma patient 1
663 (Ast1) and asthma patient 3 (Ast3). The resistin signaling pathway network is shown
664 for health control, asthma patient 1 (Ast1) and asthma patient 2 (Ast2).
665




666 **Figure 9.** The dual cell identity of the plasma blast cells in asthma patient 3. A. The
667 expression heatmap of immunoglobulin (IGLV or IGHV) genes and T cell receptor
668 (TRBV or TRAV) genes in the plasma blast cells of four sample groups. B. The violin
669 plot of CD38, CD19, CD27, CD8A, CD40LG, GNLY and NKG7 gene expression
670 levels across CD4+ T cell, CD8+ T cell, NK cell and plasma blast cells among four
671 sample groups. CD38 and CD19 for the markers for plasma blast cells. CD27 is the
672 marker for both plasma blast cells and T cells. CD8A, CD40LG, GNLY and NKG7
673 are the markers for T cells.




674 **Figure 10.** The expression of RETN gene in four sample groups. The level of serum
675 resistin between asthma patients and health controls(** $p < 0.001$).
676

677 **Supplemental Figures**



678 **Supplemental Figure 1.** Integrated single-cell profiling of PBMCs for four sample
679 groups. A. The predicted cell types for the integrated single-cell profiling of PBMCs
680 for four sample groups B. Expression of canonical gene markers for each cell type in
681 four sample groups based on integration analysis. C. The detailed classification and
682 proportion of T cells for all seven samples in our study.
683



684 **Supplemental Figure 2.** Pseudo-time analysis of all cells in four sample groups. A.


685 The proportion of major cell types in each state for healthy controls. B. The

686 proportion of major cell type in each state for asthma patient 1 (Ast1). C. The


687 proportion of major cell type in each state for asthma patient 2 (Ast2). D. The

688 proportion of major cell type in each state for asthma patient 3 (Ast3).


689




690 **Supplemental Figure 3.** The number of incoming and outgoing interactions for each
691 cell type in four sample groups. A. The number of incoming and outgoing interactions
692 in health control. B. The number of incoming and outgoing interactions in asthma
693 patient 1 (Ast1). C. The number of incoming and outgoing interactions in asthma
694 patient 2 (Ast2). D. The number of incoming and outgoing interactions in asthma
695 patient 3 (Ast3).
696



697 **Supplemental Figure 4.** The number of incoming and outgoing interaction strength
698 for each cell type in four sample groups. A. The number of incoming and outgoing
699 interaction strength in health control. B. The number of incoming and outgoing
700 interaction strength in asthma patient 1 (Ast1). C. The number of incoming and
701 outgoing interaction strength in asthma patient 2 (Ast2). D. The number of incoming
702 and outgoing interaction strength in asthma patient 3 (Ast3).




703 **Supplemental Figure 5.** The signaling changes of DCs in three asthma patients
 704 (health control as the background). A. The signaling changes of DCs in asthma patient
 705 1 (Ast1). B. The signaling changes of DCs in asthma patient 2 (Ast2). C. The
 706 signaling changes of DCs in asthma patient 3 (Ast3).
 707




708 **Supplemental Figure 6.** The violin plot of ANXA1, ANXA2 and ANXA2 gene
709 expression levels across different cell types for four sample groups.


A



B




C




711 **Supplemental Figure 7.** The upregulated signaling from DCs to the other cell types
712 in three asthma patients. A. The upregulated signaling from DCs to the other cell
713 types in asthma patient 1 (Ast1). B. The upregulated signaling from DCs to the other
714 cell types in asthma patient 2 (Ast2). C. The upregulated signaling from DCs to the
715 other cell types in asthma patient 3 (Ast3).
716


A



B



C



718 **Supplemental Figure 8.** The downregulated signaling from DCs to the other cell
719 types in three asthma patients. A. The downregulated signaling from DCs to the other
720 cell types in asthma patient 1 (Ast1). B. The downregulated signaling from DCs to the
721 other cell types in asthma patient 2 (Ast2). C. The downregulated signaling from DCs
722 to the other cell types in asthma patient 3 (Ast3).